c-Met-IN-19

c-Met-IN-19

• UNSPSC Description: c-Met-IN-19 (Compound 21j) is a c-Met inhibitor (IC50: 1.99 nM). c-Met-IN-19 shows cytotoxicity against A549, HT-29, SGC-7901, MDA-MB-231 cells with IC50s of 0.25, 0.36, 0.98, 0.76 μM[1].
• Target Antigen: c-Met/HGFR
• Type: Reference compound
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/c-met-in-19.html
• Solubility: 10 mM in DMSO
• Smiles: COC1=CC2=C(N=CC=C2OC3=CC=C(NC(CCOC)=NS(=O)(CC4=C(Cl)C=CC=C4Cl)=O)C=C3F)C=C1OCCCN5CCOCC5
• Molecular Weight: 735.65
• References & Citations: [1]Nan X, et al. Design, synthesis and biological evaluation of sulfonylamidines as potent c-Met inhibitors by enhancing hydrophobic interaction. Org Biomol Chem. 2023 Sep 20;21(36):7459-7466.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported